LL-37 Side Effects: What the Trials Actually Measured

REVIEWED BY

Marcus Reinhardt — Chemical Researcher, Lead Analyst & Peptide Research Advisor

Marcus Reinhardt is a chemical researcher specializing in sustainable materials and advanced formulation science, with research experience in compound development and health optimization. He reviews all Peptide Insider educational content for scientific accuracy, strength of supporting evidence, and practical relevance. Editorial team.

LL-37 side effects — what the trials actually measured

Written by Marcus Reinhardt · Lead Analyst, Peptide Insider · LinkedIn

Evidence-first peptide coverage — every claim on this page is linked to its primary source and reviewed against our editorial policy

Citations verified against PubMed · Published: 2026-09-04 · Last updated: 2026-09-07

LL-37 side effects have been measured in one placebo-controlled human trial: HEAL LL-37, a 148-patient phase IIb study of topical LL-37 for venous leg ulcers, which called the drug “well tolerated and safe in both dose strengths” and found no significant healing benefit in the full population (PMID 34687253). The only other human record is one dermatologic-toxicity case from intratumoral injections in a phase 1 melanoma trial (PMID 29665030). LL-37 is the body’s own antimicrobial peptide, it starts inflammation by design, and elevated levels are associated with rosacea, lupus, colitis, and melanoma invasion. This page gives you what was measured, with citations.

Quick Answer: The Most Common LL-37 Side Effects

The 148-patient HEAL LL-37 trial (topical 0.5 or 1.6 mg/mL versus placebo) reported the drug “well tolerated and safe in both dose strengths” — and published no per-event rates, so there is no percentage to quote. The one documented human adverse event comes from intratumoral injections in a phase 1 melanoma trial: multiple verrucous papules and a vesiculo-bullous lesion about 45 days into 8 weekly injections, resolving within 2 months of stopping. In mice, 20 consecutive days of intradermal injections produced rosacea-like lesions that did not fully recover. Self-reported experiences from Reddit are summarized further down; they are anecdotes, not data.

★The Documented Experience of 148 Trial Participants

The most complete “user experience” of LL-37 belongs to the 148 HEAL LL-37 patients — mean age 67.6 years, ulcers open a median of 20.3 months and averaging 11.6 cm² — who had LL-37 or placebo applied to their wounds under compression in a double-blind protocol (PMID 34687253). The investigators’ entire tolerability statement is one sentence — “well tolerated and safe in both dose strengths” — with no event table and no placebo comparison for any named event.

The one participant-level account is the melanoma phase 1 case: 8 weekly intratumoral injections, then a widespread skin eruption at about 45 days that cleared within 2 months of stopping (PMID 29665030). Both came with clinics, pharmaceutical-grade product, and monitoring. None of that ships with a research vial.

Compiled from the published trials (PMID 34687253, PMID 29665030) — not from testimonials. When we publish an individual account here, it will be a real person, named with permission.

Research peptide vial

Looking for Lab-Tested Peptides?

Our top-rated vendor publishes batch COAs and third-party testing on every compound — get up to 30% off your first order.

Shop Amino Club →

Affiliate link — it doesn’t change what we report. All compounds sold strictly for non-human research use. Read our full Amino Club review.

In This Guide

What Is LL-37?

LL-37 is the only cathelicidin humans make — a naturally occurring 37-amino-acid antimicrobial peptide produced by neutrophils and epithelial cells as part of innate defense in skin and gut (PMID 29665030, PMID 27135484). Promore Pharma AB developed a topical formulation, ropocamptide, for venous leg ulcers; its phase IIb trial supplies nearly all the human safety data here (PMID 34687253). A separate phase 1 trial injected LL-37 into melanoma skin metastases (PMID 29665030). Research-market listings sell it as an “immune modulator” for wound healing and infection — language New Zealand’s Medsafe flagged in June 2025 — typically as an injectable, a route with no published human safety data.

How It Works — Inflammation Is the Mechanism

Cathelicidins kill microbes by binding negatively charged membranes and, in Medsafe’s summary, “induce upregulation of inflammatory cytokines and chemokines, increase phagocytosis, and are chemotactic for mast cells” (Medsafe, June 2025). LL-37 also activates P2X7 and EGF receptors and drives neutrophil chemotaxis; a streptococcal protease that cleaves it into fragments of 8 and 29 amino acids keeps the bactericidal activity but, at sub-bactericidal concentrations, abolishes that host signaling (PMID 33657368). In lupus research, LL-37-DNA complexes push plasmacytoid dendritic cells to produce type I interferon via FcγRII and TLR9 (PMID 32743514). LL-37’s side effects are not off-target; immune-cell recruitment and interferon signaling are the mechanism. See also our peptides for inflammation guide.

KEY TAKEAWAY

LL-37 is an inflammation-initiating peptide sold as an anti-inflammatory. Every animal toxicity finding below is that mechanism doing its job.

The Trial Numbers That Matter

HEAL LL-37: phase IIb, double-blind, randomized, placebo-controlled, 148 patients with hard-to-heal venous leg ulcers, three arms — topical LL-37 at 0.5 mg/mL, 1.6 mg/mL, or placebo — with compression therapy (PMID 34687253). Full population: no significant improvement versus placebo. Post hoc, in wounds of at least 10 cm²: significant improvement in several healing parameters. Disclosure: three authors were Promore Pharma AB employees, one a minority shareholder, and Promore is developing LL-37 as ropocamptide. The melanoma phase 1: intratumoral injections in patients with cutaneous metastases, reaching the literature as one case report (PMID 29665030). Mouse data: intranasal LL-37 in C57BL/6 mice examined at 24 hours (PMID 26346056), and intradermal LL-37 every 12 hours for 20 consecutive days in Balb/c mice (PMID 37185701).

Adverse-Event Rates: What “Well Tolerated” Contains

The number of adverse-event percentages in the HEAL abstract: zero. The safety result is a sentence — “The study drug was well tolerated and safe in both dose strengths” — and notice what it is not: an event table, a discontinuation count, or a comparison with placebo on any named event (PMID 34687253). In 148 patients with a mean age of 67.6 years, adverse events almost certainly occurred in all three arms; the abstract doesn’t say what they were. It was, at least, judged against a placebo arm — on an open ulcer under a bandage, not from a vial.

PERSONAL OBSERVATION — PI EDITORIAL

Reading the HEAL abstract beside the melanoma case report, what struck us was the asymmetry. The trial with 148 people gives safety one sentence; the report on one patient gives it 12 biopsies and a paragraph of histology. Toxicity gets written up when it’s interesting, tolerability gets summarized when it isn’t — which leaves “well tolerated” carrying a lot of weight on little visible support.

Dermatologic Toxicity: The Phase 1 Melanoma Case

The one detailed human adverse-event record is a 2018 case report from MD Anderson (PMID 29665030). A 63-year-old woman with stage IIIC melanoma, progressed through nivolumab and combination chemotherapy, received 8 weekly intratumoral LL-37 injections. The injected lesions shrank. Approximately 45 days after the first injection, she developed multiple verrucous papules and a vesiculo-bullous lesion on the trunk and extremities. Of 12 skin biopsies, 11 showed a lichenoid inflammatory infiltrate with eosinophils beneath an atypical squamous proliferation with verrucous, keratoacanthoma-like features; 11/12 showed no spongiosis. All lesions resolved within 2 months of stopping LL-37. This is one heavily pretreated cancer patient on an intratumoral route, not a rate. What it establishes: exogenous LL-37 can produce a widespread, biopsy-confirmed inflammatory skin eruption in a human, weeks in, reversible on cessation.

Injection-Site Reactions: The Route Nobody Studied

In HEAL the “site” was the ulcer itself, and the abstract reports no local reaction rates — not zero, not reported (PMID 34687253). In the melanoma phase 1 the site was the tumor; injected lesions showed “interval clinical shrinkage,” and the toxicity appeared on the trunk and extremities — an eruption, not an injection-site reaction (PMID 29665030). The closest thing to injection-site data is Balb/c mice injected intradermally every 12 hours: rosacea-like lesions expanding over the first 13 days, then plateauing, with collagen deposition after 20 consecutive days (PMID 37185701). Research-market LL-37 ships as lyophilized powder to be reconstituted and injected subcutaneously — a route with no published human safety data of any kind.

PRACTICAL NOTES — WHAT THE ROUTES ACTUALLY TESTED

  • In the mouse intradermal model, short-term exposure recovered fully; 20 consecutive days did not (PMID 37185701)
  • Sterile technique — clean site, single-use needles — is non-negotiable in any protocol, trial or lab
  • Our bacteriostatic water guide covers reconstitution handling in detail

Beyond the Wound: The Association Literature

None of these studies gave LL-37 to a human and watched for disease — association, not causation. Rosacea: a 2026 review names the TLR2/LL-37/mTORC1 axis a core pathway (PMID 41646975), and labs induce rosacea-like lesions in mice with LL-37 (PMID 37185701). Chronic rhinosinusitis: LL-37 is elevated in patients (PMID 26346056). Lupus: LL-37-DNA complexes chronically activate plasmacytoid dendritic cells, anti-LL-37 antibodies appear in patients, and reviewers propose it as a biomarker (PMID 32743514). Inflammatory bowel disease: overexpressed in ulcerative colitis mucosa, unchanged in Crohn’s, yet protective in animal models and patients — “intricate,” the reviewers say (PMID 27135484); see our peptides for gut health coverage. Melanoma: LL-37-expressing cells rise with T stage across Tis-T4, and LL-37 (and its mouse ortholog CRAMP) raised pro-angiogenic factors including CXCL5, IL23A, and MMP9 in melanoma cells and MMP-1 in M2 macrophages (PMID 36980564) — the opposite of what the phase 1 hoped for. Collectively: LL-37 is not inert, and its company is inflammatory and autoimmune. See also peptides for acne.

What Users Report: Self-Reported Effects From Reddit

The 148-patient trial above applied LL-37 to a wound and the melanoma study injected it into a tumor; nobody has published what happens when people inject it under the skin or spray it up their nose, which is how it is used outside trials. The only accounts of that come from self-reports, and they live in an unusual place: not the bodybuilding or nootropic subreddits but the chronic-illness ones, where LL-37 is discussed as a home antibiotic for SIBO, Lyme, mold and “CIRS.” We searched Reddit on September 4, 2026, and read the comment threads of eight LL-37 discussions across r/Peptides, r/SIBO, r/Lyme, r/Biohacking and r/CIRS. Everything below is paraphrased and linked, uses no usernames, and describes products nobody verified.

The recurring report is an acute inflammatory-type reaction, which users reinterpret as proof of effect. A poster who took a first dose at night woke with joint pain, body aches and a burning sensation across the body and asked whether that was normal; a reply reported feeling noticeably ill after the second dose of a second cycle and more fatigue than usual in the first, and the thread’s advice was to cut the dose (r/Peptides). In r/Lyme, users described the first few days as flu-like with a low-grade fever, a reaction that eased when the dose was lowered, and one user who felt sick each time he stopped and ran it for three to four months (thread). An r/SIBO poster two weeks into 250 mcg daily under a doctor’s protocol felt persistently off with worse brain fog and called it a herx from mold and heavy metals (thread). The word “herx,” borrowed from the die-off reaction to antibiotics in syphilis, does the work of turning every unpleasant symptom into evidence the peptide is killing something. The mouse data above, in which LL-37 itself provokes acute inflammation in nasal tissue and rosacea-like skin lesions, offers the other reading.

The most striking single report is facial swelling. A commenter who took two very low doses woke after the second with a face so swollen he could barely see, compared it to a bee-sting allergy, said it took a week to subside and damaged his skin barrier, and swore off the compound (r/Biohacking). An r/SIBO user reported that two attempts each increased knee and joint inflammation and caused sleepless, painful nights, and that he later found literature saying LL-37 can worsen rheumatoid and osteoarthritis inflammation (thread). The original poster of that thread had read claims that LL-37 was somewhat toxic and had ruined people’s lives, hearsay he could not source.

Users themselves circulate the mechanistic worries. One commenter told an enthusiast that LL-37 is pro-inflammatory and increases LDL uptake by macrophages, implying atherosclerosis risk (r/Peptides); another linked psoriasis literature and said it would not surprise him if giving someone LL-37 caused a flare; a third called it the opposite of longevity, capable of triggering autoimmune flares and cytotoxicity. A Lyme user who ran three 5 mg cycles over a year advised being careful about running it too high or too long (thread).

Benefit reports are real but entangled. The most-upvoted positive account is a poster whose long-standing food-allergy reactions, including a history of rash and throat swelling, faded during a cycle of LL-37 plus thymosin alpha-1, returned partially after stopping, and who later aborted an allergic flare with a dose; he reported no side effects at 150 mcg (thread). Others credited a single 250 mcg dose with relieving gum-infection pain within hours, a 200 mcg nasal spray (reconstituted with colloidal-silver water, a red flag on its own) with resolving chronic sinusitis, and a three-month course with knocking back but not clearing Lyme coinfections. In r/SIBO, long-time members noted that LL-37 has been discussed for years without anyone reporting success against SIBO, and that for mold and autoimmune use it had made some people worse and some better (thread). In a 76-comment CIRS stack thread, the benefits were credited mainly to VIP, not LL-37 (thread).

Doses and routes are improvised. Reports range from 25 mcg to 500 mcg a day and multi-milligram “cycles,” by subcutaneous injection or self-made nasal spray, nearly always stacked with thymosin alpha-1, KPV, VIP or BPC-157. A German commenter proposed the obvious control, filling some bottles with saline and not knowing which is which, and nobody in the thread had done it.

HOW TO READ SELF-REPORTS

Joint aches, burning, fever, flu-like malaise and one case of facial swelling are what users report, and most of them decided it meant the peptide was working. LL-37 is a molecule the body deploys to start inflammation, so those reports are at least as consistent with the peptide doing exactly what it does in the mouse studies as with any pathogen dying. The published human record cannot adjudicate, because no trial has ever injected it.

When Side Effects Happen — and When They Fade

No LL-37 data supports a week-by-week calendar; what exists are three timestamps. Fast: a single intranasal challenge in mice produced inflammation by 24 hours (PMID 26346056). Subacute: the one human eruption appeared approximately 45 days into weekly intratumoral injections and resolved within 2 months of cessation (PMID 29665030). Cumulative: in mice injected every 12 hours, lesions grew through the first 13 days then stabilized; short-term exposure recovered, 20 consecutive days did not (PMID 37185701). Hours in mice, weeks in the one human, and reversibility tied to duration.

Long-Term Safety: What the Published Exposures Can’t Tell You

The HEAL abstract does not state treatment duration or follow-up, so we can’t say how long the 148 patients were exposed (PMID 34687253). The longest human exposure in our sources is 8 weekly injections (PMID 29665030). The longest exposure with histology is 20 consecutive days — in mice — where lesions became irreversible, with collagen deposition and skin that did not completely recover (PMID 37185701). No multi-month human safety data exists by any route. Anyone describing LL-37’s long-term profile is forecasting, not reporting.

Who the Trials Enrolled

HEAL enrolled patients with hard-to-heal venous leg ulcers — mean age 67.6 years, median ulcer duration 20.3 months, mean wound 11.6 cm² — all on compression therapy (PMID 34687253). The melanoma phase 1 enrolled patients with cutaneous metastases; the case-report patient had stage IIIC disease that had failed nivolumab and chemotherapy (PMID 29665030). A separate 19-patient serum study shows how venous-ulcer research screens, excluding non-venous etiology, compression intolerance, active vein thrombosis, wound infection, and kidney insufficiency (PMID 27663530). Nothing in the human record describes a healthy adult taking LL-37 systemically for “immune support.”

Managing and Minimizing Side Effects: What the Trials Did

The only documented management of an LL-37 adverse effect in a human was stopping it: injections ceased and every lesion resolved within 2 months (PMID 29665030). HEAL’s lever was concentration — 0.5 and 1.6 mg/mL, both judged well tolerated, no differential reported (PMID 34687253). In the mouse skin model the lever was duration: short-term administration produced inflammation that recovered; 20 consecutive days added collagen hyperplasia that did not (PMID 37185701). No premedication, co-treatment, or dose-adjustment rule appears in any abstract. We report this as study design, not protocol.

Dose and Side Effects: Measured in Mice, Not Humans

No human dose-toxicity gradient exists: HEAL’s 0.5 and 1.6 mg/mL arms were both “well tolerated and safe,” with no difference reported (PMID 34687253). In mice the relationship is explicit: intranasal LL-37 at increasing concentrations produced significantly more inflammatory change (p < 0.01), with higher myeloperoxidase and dose-dependent mast-cell infiltration (p < 0.01) (PMID 26346056). We list what the trials administered, not doses, cycles, or schedules — none has been tested by the route a vial implies.

DID YOU KNOW

LL-37 is what dermatology labs inject to create rosacea-like lesions in mice — used because it reliably produces the disease’s inflammation and, with long enough exposure, collagen deposition (PMID 37185701). The compound sold as a skin-healing agent is the one dermatology labs use to make a skin disease model.

LL-37 Alone vs Stacked: What the Data Covers

No combination trial of LL-37 exists. The only “stack” in the human literature is HEAL’s: LL-37 plus compression therapy — a bandage (PMID 34687253). Forum pairings with BPC-157, TB-500, KPV, or copper peptides have no published human safety data, and LL-37’s documented actions are inflammatory recruitment and interferon signaling (PMID 33657368, PMID 32743514), while the peptides it’s stacked with are marketed for the opposite effect. The BPC-157 and TB-500 stack has its own page; nothing there transfers to a combination that includes LL-37.

How LL-37 Compares to BPC-157, TB-500, and KPV

No head-to-head trial exists between LL-37 and any other research-market wound or immune peptide, so every comparison is cross-literature — different populations, routes, and reporting standards. What sets LL-37 apart is the kind of evidence it has. Most peptides sold beside it have no placebo-controlled trial; LL-37 has one, and it found no healing benefit in its full population (PMID 34687253). Most have no published human toxicity report; LL-37 has a biopsy-confirmed one (PMID 29665030). Start with our BPC-157 and TB-500 primers and our KPV coverage — none of their findings apply here.

Where the Trial Data Stops: The Research-Vial Reality

Everything above describes pharmaceutical-grade ropocamptide on a wound under compression, or LL-37 injected into tumors on an oncology unit. A lyophilized vial from a research storefront shares a sequence with those products and nothing else verifiable without testing. The usual gaps apply — identity and purity (a batch-matched COA is the only evidence the vial contains dose-accurate LL-37), concentration arithmetic (reconstitution with bacteriostatic water is on the buyer; our peptide calculator handles the math and nothing else), and no medical monitoring. LL-37 adds a fourth: route. Vials are bought to be injected subcutaneously; the human data is topical and intratumoral. IGF-1 LR3 has the same gap. Compounds in this channel are sold strictly for non-human research use.

Sourcing and Verification

The checklist doesn’t change: a batch-matched COA naming compound and quantity — our COA reading guide shows what to look for — independent third-party testing with a verifiable report number, and skepticism toward any listing invoking “clinical trials” without mentioning that the only placebo-controlled one found no efficacy in its full population. (Disclosure: some links on this site are affiliate links; they don’t change what we report.) Our vendor reviews show what passing documentation looks like, and our guide library covers verification in depth.

US Regulatory Status

LL-37 is not FDA-approved in any form; ropocamptide remains investigational. The clearest statement on the category comes from New Zealand: in a June 2025 submission, Medsafe noted that “peptides belonging to the cathelicidin family (such as LL-37) are being marketed as immune modulators for use in wound healing, tissue regeneration, and infection,” and recommended that antimicrobial peptides and their precursors be classified as prescription medicines as a group entry, naming LL-37 and CAP-18 (Medsafe, June 2025). Its background notes that products sold “for research purposes only” are bought by individuals intending to administer them, and names the aim as “mitigating both the known and unknown clinical risks.” The same document runs through this batch — see our Adamax and Pinealon pages.

PERSONAL OBSERVATION — PI EDITORIAL

In listings we’ve reviewed, LL-37 is sold on “immune support” and “wound healing.” Set those beside the record: the one placebo-controlled trial found no healing benefit in its full population, the regulator that looked hardest at the category concluded prescription-only, and dermatology labs use this peptide to give mice a skin disease. We cover many compounds where marketing runs ahead of evidence, and few where they point in opposite directions.

Frequently Asked Questions

What are the most common LL-37 side effects?

None have been quantified. The 148-patient HEAL LL-37 trial of topical LL-37 said only that it was “well tolerated and safe in both dose strengths.” The one detailed human report is a melanoma patient whose skin eruption appeared about 45 days into intratumoral injections and resolved within 2 months of stopping.

Is LL-37 safe to inject?

No published human study has tested subcutaneous LL-37. The human data is topical application to leg ulcers and intratumoral injection into melanoma. In mice, intradermal injections every 12 hours for 20 consecutive days produced rosacea-like lesions that did not fully recover.

Does LL-37 cause skin reactions or rosacea?

In one human case, intratumoral LL-37 produced verrucous papules and a vesiculo-bullous lesion, confirmed on 11 of 12 biopsies, that cleared after cessation. LL-37 is used to induce rosacea-like lesions in mice, and a 2026 review places the TLR2/LL-37/mTORC1 axis at the center of rosacea pathogenesis. Association and mechanism, not proof of causation.

Did LL-37 work for wound healing in trials?

Not in the primary analysis. HEAL LL-37 found no significant improvement versus placebo across all 148 patients. A post hoc analysis reported a benefit in wounds of at least 10 cm2, which the sponsor-affiliated authors said warrants an adequately powered follow-up study.

Is LL-37 linked to autoimmune disease or cancer?

By association. LL-37-DNA complexes drive type I interferon in lupus research, LL-37 is overexpressed in ulcerative colitis mucosa, and LL-37-expressing cells rise with melanoma T stage while LL-37 pushes melanoma cells toward invasion in the lab. None of these gave exogenous LL-37 to humans and measured disease; causation is unestablished.

Is LL-37 FDA-approved or legal to buy?

It is not FDA-approved; ropocamptide is investigational. Vials are research-market material for non-human research use. In June 2025, New Zealand’s Medsafe recommended classifying antimicrobial peptides such as LL-37 as prescription medicines.

Glossary of Terms

  • Cathelicidin: a family of cationic antimicrobial peptides in the innate immune system; LL-37 is the only one humans produce.
  • Ropocamptide: the non-proprietary name under which Promore Pharma AB is developing topical LL-37 for venous leg ulcers.
  • CAP-18: a cathelicidin precursor named alongside LL-37 in Medsafe’s June 2025 submission.
  • Plasmacytoid dendritic cell (pDC): an immune cell that LL-37-DNA complexes stimulate to produce type I interferon.
  • Post hoc analysis: a subgroup analysis defined after the data are in — hypothesis-generating, not confirmatory.
  • Intratumoral injection: injecting a drug directly into a tumor — the melanoma trial’s route, unrelated to subcutaneous dosing.
  • COA (certificate of analysis): the lab document identifying a research vial’s contents; batch-matched or it proves nothing.

References